Valantin, M A <br/><br/>
Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients.  [electronic resource] 

 -  The Journal of antimicrobial chemotherapy  Mar 2010 
 - 556-61 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1460-2091 
<br/><br/><label>Standard No.: </label>10.1093/jac/dkp462  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenine--adverse effects<br/>Adult<br/>Anti-HIV Agents--adverse effects<br/>Cholesterol, LDL--blood<br/>Deoxycytidine--adverse effects<br/>Emtricitabine<br/>Female<br/>HIV Infections--drug therapy<br/>Humans<br/>Male<br/>Middle Aged<br/>Nucleosides--adverse effects<br/>Organophosphonates--adverse effects<br/>Tenofovir<br/>Triglycerides--blood